Viking Therapeutics, Inc.

Viking Therapeutics Misses on Revenue, Stock Down 3.79%

This earnings report shows that while Viking Therapeutics managed to beat EPS expectations, the lack of revenue data and guidance may have raised concerns among investors. The stock reacted negatively, dropping 3.79%, likely due to uncertainty about future performance and the absence of concrete updates from management.